Sabra Health Care REIT, Inc.
SBRA
$17.27
$0.342.01%
| Weiss Ratings | SBRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Fair | |||
| Risk Grade | C | |||
| Reward Grade | B | |||
| Rating Factors | SBRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Excellent | |||
| Growth Index | Good | |||
| Efficiency Index | Good | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | SBRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.74 | |||
| Price History | SBRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -1.31% | |||
| 30-Day Total Return | 4.98% | |||
| 60-Day Total Return | 4.68% | |||
| 90-Day Total Return | -7.00% | |||
| Year to Date Total Return | 3.15% | |||
| 1-Year Total Return | 35.01% | |||
| 2-Year Total Return | 76.87% | |||
| 3-Year Total Return | 64.32% | |||
| 5-Year Total Return | 104.95% | |||
| 52-Week High % Change | -15.48% | |||
| 52-Week Low % Change | 27.25% | |||
| Price | SBRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $20.03 | |||
| 52-Week Low Price | $13.31 | |||
| 52-Week Low Price (Date) | Apr 18, 2024 | |||
| 52-Week High Price (Date) | Nov 12, 2024 | |||
| Valuation | SBRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 4.03B | |||
| Enterprise Value | 6.37B | |||
| Price/Earnings (TTM) | 31.67 | |||
| Earnings Per Share (TTM) | 0.53 | |||
| Earnings Per Share Growth | 995.29% | |||
| Price/Earnings To Growth | 0.03 | |||
| Price/Sales (TTM) | 5.77 | |||
| Price/Book (Q) | 1.47 | |||
| Enterprise Value/Revenue (TTM) | 9.06 | |||
| Price | $17.27 | |||
| Enterprise Value/EBITDA (TTM) | 15.10 | |||
| Enterprise Value/EBIT | 24.76 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | SBRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 239.64M | |||
| Dividend Yield | 7.09% | |||
| Div. Per Share (Most Recent) | $0.30 | |||
| Dividend Per Share (TTM) | $1.20 | |||
| Payout Ratio (TTM) | 221.09% | |||
| Dividend Per Share (Most Recent) | $0.30 | |||
| Company Info | SBRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 888 393 8248 | |||
| Address | 1781 Flight Way Tustin, CA 92782-0539 | |||
| Website | www.sabrahealth.com | |||
| Country | United States | |||
| Year Founded | 2010 | |||
| Profitability | SBRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 36.57% | |||
| Profit Margin | 18.01% | |||
| Management Effectiveness | SBRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 3.01% | |||
| Return on Equity | 4.57% | |||
| Income Statement | SBRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 381.50M | |||
| Total Revenue (TTM) | 703.54M | |||
| Revenue Per Share | $2.94 | |||
| Gross Profit (TTM) | 477.02M | |||
| EBITDA (TTM) | 422.09M | |||
| EBIT (TTM) | 257.33M | |||
| Net Income (TTM) | 126.71M | |||
| Net Income Avl. to Common (TTM) | 126.71M | |||
| Total Revenue Growth (Q YOY) | 12.49% | |||
| Earnings Growth (Q YOY) | 172.18% | |||
| EPS Diluted (TTM) | 0.53 | |||
| EPS Diluted Growth (Q YOY) | 182.81% | |||
| Balance Sheet | SBRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 81.94M | |||
| Cash Per Share (Q) | $0.34 | |||
| Total Current Assets (Q) | 236.96M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 2.74B | |||
| Current Ratio (Q) | 2.002 | |||
| Book Value Per Share (Q) | $11.54 | |||
| Total Assets (Q) | 5.30B | |||
| Total Current Liabilities (Q) | 118.34M | |||
| Total Debt (Q) | 2.43B | |||
| Total Liabilities (Q) | 2.56B | |||
| Total Common Equity (Q) | 2.74B | |||
| Cash Flow | SBRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -109.00M | |||
| Cash from Financing (TTM) | -181.56M | |||
| Net Change in Cash (TTM) | 19.62M | |||
| Levered Free Cash Flow (TTM) | 245.27M | |||
| Cash from Operations (TTM) | 310.54M | |||
